Glaukos Corporation recently unveiled its Investor Presentation, focusing on its core growth strategy involving leading-edge innovation aimed at addressing clinical needs within large or underserved patient populations. The company is committed to challenging conventional paradigms to enhance care standards and outcomes through dropless therapies and commercial excellence. Glaukos highlights its innovation-driven approach with five novel platforms, including iStent, iDose, iLink, iLution, and Retina XR, targeting four therapeutic areas: Glaucoma, Rare Disease, Anterior Segment, and Posterior Segment. The presentation also emphasizes significant investment in research and development since 2018, with disclosed pipeline programs in 2025 increasing significantly from 2015. Key commercial catalysts for 2025-26 focus on foundational therapies that elevate care standards. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.